Dr. John F. Dipersio, MD

Dr. Dipersio practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Dipersio's NPI, 1730106295, was assigned on July 17, 2006. Dr. Dipersio graduated from University of Rochester Medical Center in 1980. Dr. Dipersio holds Missouri license 105204.

Dr. Dipersio's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Dipersio also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Dipersio's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Dipersio is also affiliated with Christian Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Dipersio to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dipersio practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dipersio's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dipersio is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dipersio's licenses on file in 4 states: Missouri, California, Illinois and New York.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Dipersio treats.

CMS data shows 8,097 Medicare services from Dr. Dipersio across 25 procedure codes in 2024, for 346 Medicare patients. Medicare paid $193,954 for them.

CMS counts 346 Medicare patients who saw Dr. Dipersio in 2024. The largest group is 65 to 74, with 172 patients. 68% of them have high blood pressure, and 64% have high cholesterol. 16% are also on Medicaid. Their average risk score is 3.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dipersio's median patient age at 69, with 45% women.

In 2024, Dr. Dipersio wrote 1,818 Medicare Part D claims for 150 patients. 77% of them were for generic drugs. CMS names the drug for 1,392 of them, across 41 drugs with 11 or more claims each, at $4,624,751 in total drug cost. In 2023, CMS named 1,751 claims across 58 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Dipersio for performance year 2024, reported as part of a group. Dr. Dipersio accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 547 papers to Dr. Dipersio, published from 2002 to 2025. 2016 was the busiest year, with 42. The most frequent topics are Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute and Graft vs Host Disease. Dr. Dipersio has published most often in Blood. Dr. Dipersio's most frequent co-authors are Peter Westervelt, MD, Mark Andrew Schroeder, MD and Geoffrey Lim Uy, MD.

Dmand AI links Dr. Dipersio to 48 clinical trials, 13 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Multiple Myeloma and Myelodysplastic Syndromes. Washington University School of Medicine sponsors the most, 28. Open Payments lists research payments to Dr. Dipersio that name 2 trials.

CMS Open Payments shows 106 general payments to Dr. Dipersio from 18 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Incyte Corporation paid the most, $118,242. It also lists 64 research payments totaling $45,056 from 2016 to 2017, naming 2 clinical trials.

Dmand AI lists 8 awards for Dr. Dipersio, most recently Legacy Award in 2016.

Dr. Dipersio graduated from University of Rochester Medical Center in 1980. Dr. Dipersio is a member of AACR Science Policy and Government Affairs Committee (SPGAC), AACR, ACP, American Society of Blood and Marrow Transplantation, ASCO and Board of Scientific Councilors, National Cancer Institute.

Dr. Dipersio is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.